Focal segmental glomerulosclerosis and Pulmonary embolism

Summary:

Pulmonary embolism is found among people with Focal segmental glomerulosclerosis, especially for people who are male, 60+ old.

The study analyzes which people have Pulmonary embolism with Focal segmental glomerulosclerosis. It is created by eHealthMe based on reports of 38 people who have Focal segmental glomerulosclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Focal segmental glomerulosclerosis?

Focal segmental glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli) is found to be associated with 176 drugs and 396 conditions by eHealthMe. Check the latest studies of Focal segmental glomerulosclerosis.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,333 drugs and 2,956 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

On Jul, 17, 2026

38 people who have Focal Segmental Glomerulosclerosis and Pulmonary Embolism are studied.

Would you have Pulmonary embolism when you have Focal segmental glomerulosclerosis?

Gender of people who have Focal Segmental Glomerulosclerosis and experienced Pulmonary Embolism *:

female: 6.9 %
male: 93.1 %

Age of people who have Focal Segmental Glomerulosclerosis and experienced Pulmonary Embolism *:

Common co-existing conditions for these people *:

Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 5 people, 13.16%
High Blood Pressure: 2 people, 5.26%
Cellulitis (infection under the skin): 2 people, 5.26%
Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 1 person, 2.63%
Pain: 1 person, 2.63%
Cyst (a closed sac): 1 person, 2.63%
Cryptococcosis (potentially fatal fungal disease): 1 person, 2.63%
Birth Control: 1 person, 2.63%
Asthma: 1 person, 2.63%

Common drugs taken by these people *:

Furosemide: 28 people, 73.68%
Amlodipine: 27 people, 71.05%
Acetaminophen: 26 people, 68.42%
Tacrolimus: 26 people, 68.42%
Diphenhydramine Hydrochloride: 26 people, 68.42%
Trandolapril: 26 people, 68.42%
Tizanidine Hydrochloride: 16 people, 42.11%
Methylprednisolone: 13 people, 34.21%
Farxiga: 5 people, 13.16%
Prednisolone: 3 people, 7.89%

Common symptoms for these people *:

Drug Ineffective: 17 people, 44.74%
Cryptococcosis (potentially fatal fungal disease): 5 people, 13.16%
Cellulitis (infection under the skin): 5 people, 13.16%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 13.16%
Skin Ulcer: 3 people, 7.89%
Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 2 people, 5.26%
Disseminated Cryptococcosis (one of the acquired immune deficiency syndrome defining criteria and the most common cause of life threatening meningitis): 2 people, 5.26%
Thrombocytopenia (decrease of platelets in blood): 2 people, 5.26%
Nephropathy Toxic (damage to kidney due to toxins): 2 people, 5.26%
Pain: 2 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition

Related studies:

Treatments, associated drugs and conditions:

Focal segmental glomerulosclerosis (2,786 reports)
Pulmonary embolism (160,407 reports)

All the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,333 drugs)

All the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,956 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Pulmonary embolism and Focal segmental glomerulosclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.